Peter A. Crooks
Sourced from institutional research profiles (UAMS TRI or ARA).
Drug research
Also affiliated: Southern Research Institute (1990–1993); National Institute of Technology Warangal (2008–2015); The Graduate Center, CUNY (1986–2001); Uppsala University (1993); University of London (1984); University of Kentucky HealthCare (2003); University of Minnesota (1988–1989); Main Line Health (2007); Kaiser Permanente (2008); University of Wisconsin–Madison (2013); University of Kentucky (1982–2024); Gdańsk University of Technology (2014); American Association of Colleges of Pharmacy (2018); Vanderbilt University (2013); Trinity College Dublin (2024); University of Arkansas Medical Center (2013–2014); Albert B. Chandler Hospital (1993–2007); Markey Cancer Center (2003); Hennepin County Medical Center (1988–1989); University of Manchester (1970–1989); University of Rochester Medicine (2008); Yale University (1978–1980); University of Florida (2009–2019); Pharmaceutical Biotechnology (Czechia) (2002); Arkansas Department of Agriculture (2013); Vanderbilt Health (2013); Institute of Pharmacology (1995); Wake Forest University (2008); Belmont University (2013); University of Colorado Anschutz Medical Campus (2015); Indiana University – Purdue University Indianapolis (2008); Cardiff University (2010); University of Birmingham (2010); California College of the Arts (2010); Manchester University (1970–1980); Vanderbilt University Medical Center (2013); University of Colorado Denver (2015); Florida College (2009); University of California, Berkeley (2013)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Peter A. Crooks' research focuses on drug design and discovery, with a significant emphasis on cancer-related therapeutics. His work spans over four decades and has resulted in over 560 publications in medicinal chemistry and drug synthesis, alongside more than 100 issued and pending patents in drug discovery. He is recognized internationally for his expertise in prodrug and codrug design, drug metabolism, and pharmacokinetics, contributing to preclinical drug development.
Crooks has founded seven startup drug discovery companies, and several of his discoveries have progressed to clinical trials. Notably, the anticancer drug Valchlor®, developed from his research, has received FDA approval for the treatment of cutaneous T-cell lymphoma. Additional drugs stemming from his work are currently in phase 1 and later-stage clinical trials.
His current research interests include studying novel compounds for neurodegenerative diseases such as Alzheimer's, investigating the antitumor properties of sesquiterpene lactone analogs as NFκB inhibitors, and exploring parthenolide's role in inducing ferroptosis in hepatocellular carcinoma cells. He also has an interest in developing polymeric membranes for renal applications and understanding the therapeutic potentials of antihypertensive agents against drug-induced cardiotoxicity.
Metrics
- h-index: 57
- Publications: 928
- Citations: 14,971
Selected Publications
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024)
-
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023)
-
High flux novel polymeric membrane for renal applications (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells (2022)
-
Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear (2021)
-
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021)
-
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021)
-
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021)
-
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity (2021)
-
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021)
-
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021)
-
Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs (2020)
-
Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands (2020)
-
Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation (2020)
ARA Academy 2011 ARA Scholar
Grants & Funding
As listed on this researcher's institutional profile.
- Development of Small Molecule Radiation Sensitizers NIH/Nat. Cancer Institute via Vanderbilt University
- Development of Novel Therapies for Methamphetamine Abuse NIH/Nat. Inst. on Drug Abuse via University of Kentucky Research Foundation
- Enhancing the prevention and treatment of orthopaedic infections associated with traumatic injury US Department of Defense
- Role of glucose transport in Alzheimer's disease pathogenesis NIH
- Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome NIH
- Covid-19 RAPID: Sprayable Cellulosic nanoparticle Coatings for COVID 19 Anti-viral Applications.
- Novel melampomagnolide B-based prodrugs for the treatment of leukemia NIH
- Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission via National Science Foundation
- Early Events in Alzheimer Pathogenesis NIH
- Center for Studies of Host Response to Cancer Therapy NIH
- Development of Novel Therapeutics for Methamphetamine Abuse - Continuation NIH/Nat. Inst. on Drug Abuse via University of Kentucky Research Foundation
- Regulation of hepatic stellate cells by intracellular calcium NIH
- RII Track-1: Arkansas ASSET Initiative III - Continuation Y5 - Continuation National Science Foundation via Arkansas Economic Development Commission
- Role of glucose transport in Alzheimer’s disease pathogenesis NIH/Nat. Inst. on Aging
Collaboration Network
Top Collaborators
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Showing 5 of 6 shared publications
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- High flux novel polymeric membrane for renal applications
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
- Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
- Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity
Similar Researchers
Based on overlapping research topics